The industry is increasingly aware of the importance of corporate social responsibility (CSR) programmes – and Alex Kalomparis, Gilead’s vice president of public affairs for EMEA, says they
ViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors confidence that patients can switch from rival triple therapies to its new two-drug
Gilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving HIV drugs from entering the market.
